113PBespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)

113PBespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)

Abstract Background Limited data exist in the clonal dynamics of serial ctDNA as a predictive biomarker in advanced solid tumor pts receiving immune checkpoint blockade. Methods Pts with mixed solid tumors received single agent P (anti-PD-1) 200 mg IV Q3wks in the investigator-initiated phase II INS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser: Yang, C, Iafolla, M A, Dashner, S, Xu, W, Hansen, A R, Bedard, P, Lheureux, S, Spreafico, A, Razak, A A, Wu, H -T, Shchegrova, S, Liu, Z A, Ohashi, P S, Torti, D, Louie, M, Sethi, H, Aleshin, A, Siu, L L, Bratman, S, Pugh, T J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Limited data exist in the clonal dynamics of serial ctDNA as a predictive biomarker in advanced solid tumor pts receiving immune checkpoint blockade. Methods Pts with mixed solid tumors received single agent P (anti-PD-1) 200 mg IV Q3wks in the investigator-initiated phase II INSPIRE trial (NCT02644369). ctDNA was assayed at baseline (B) and start of cycle 3 (C3) using a pt-specific amplicon-based NGS assay (Signatera™). Samples were considered ctDNA positive if ≥ 2 of 16 pt-specific targets met the qualifying confidence score threshold. Table: 113PEndpointORR N = 72*CBR N = 72*EndpointPFS N = 73*OS N = 73*SubgroupCR/PR N = 15SD/PD N = 57CR/PR/SD≥6 cycles N = 22CR/PR/SD
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdz239.024